Immatics N.V. (IMTX)
| Market Cap | 448.67M |
| Revenue (ttm) | 34.76M |
| Net Income (ttm) | -93.34M |
| Shares Out | 62.93M |
| EPS (ttm) | -1.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 87,366 |
| Open | 7.03 |
| Previous Close | 6.95 |
| Day's Range | 6.90 - 7.72 |
| 52-Week Range | 5.75 - 16.30 |
| Beta | 0.42 |
| Analysts | Buy |
| Price Target | 24.14 (+238.6%) |
| Earnings Date | May 31, 2022 |
About IMTX
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients wi...
Financial Performance
In 2021, Immatics's revenue was $34.76 million, an increase of 11.23% compared to the previous year's $31.25 million. Losses were -$93.34 million, -55.82% less than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for IMTX stock is "Buy." The 12-month stock price forecast is 24.14, which is an increase of 238.57% from the latest price.
News
Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo...
H ouston, Texas and Tuebingen , Germany , May XX , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...
Strength Seen in Immatics (IMTX): Can Its 5.3% Jump Turn into More Strength?
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors
Tuebingen , Germany and Houston, Texas , May 10 , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirectin...
Wall Street Analysts See a 178% Upside in Immatics (IMTX): Can the Stock Really Move This High?
The consensus price target hints at a 178.1% upside potential for Immatics (IMTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...
Immatics Announces Full Year 2021 Financial Results and Corporate Update
Tuebingen , Germany and Houston, TX , March 2 3 , 20 2 2 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirect...
Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update
Tuebingen , Germany and Houston, TX , November 16 , 20 2 1 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redire...
Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Tar...
Company to host conference call on Tuesday, November 9 at 8:30 am EST
Immatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immunotherapy of Canc...
Houston, Texas and Tuebingen, Germany, November 1, 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...
Immatics (IMTX) Stock Jumps 5.8%: Will It Continue to Soar?
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Immatics: Q2 Earnings Insights
Shares of Immatics (NASDAQ:IMTX) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share fell 21.62% year over year to ($0.45), which missed the estimate of ($0.40).
Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update
Tuebingen, Germany and Houston, TX, August 10, 2021 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting c...
BioCopy, Immatics Team Up For Characterization Of TCR-Peptide-HLA Interactions
Switzerland-based BioCopy AG has collaborated with Immatics N.V. (NASDAQ: IMTX) to characterize T cell receptors (TCRs).
BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions
BASEL, Switzerland and TÜBINGEN, Germany, July 7, 2021 /PRNewswire/ -- BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) "Immatics" in the field of characterization of T cell recept...
Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispeci...
GENEVA & DURHAM, N.C.--(BUSINESS WIRE)--Selexis SA and KBI Biopharma (KBI), both JSR Life Sciences companies, announced today that they have signed service agreements with Immatics N.V. (NASDAQ: IMTX; “...
Immatics Announces Changes to its Board of Directors
Tuebingen , Germany and Houston, Texas , May 26 , 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirectin...
Immatics Announces First Quarter 2021 Financial Results and Business Update
Tuebingen , Germany and Houston, TX , May 18 , 20 2 1 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting...
Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME
Immatics' second TCR Bispecifics program IMA402 demonstrates tumor cell killing in vitro and complete regressions of established tumors in an in vivo tumor model
Immatics Announces Full Year 2020 Financial Results and Corporate Update
Tuebingen, Germany and Houston, TX, March 30, 2021 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting ca...
Why Immatics Stock Is Soaring Today
Investors liked the company's latest clinical update.
IMTX Stock: Why Immatics Shares Are Rocketing Higher Today
A press release from the company is showing promise in shrinking cancerous tumors. The discoveries are leading to a rise in IMTX stock.
Immatics Stock Trading Higher As Cell Therapy Program Shows Anti-Tumor Activities In Pretreated Cancer Patients
Immatics NV (NASDAQ: IMTX) has announced a clinical data update from the dose-escalation cohorts of the ongoing Phase 1 trial evaluating its ACTengine product candidates IMA201, IMA202, and IMA203. Data...
Why Bluebird Bio, Onconova, FSD Pharma, Immatics Are Moving Wednesday
bluebird bio, Inc. (NASDAQ: BLUE), Onconova Therapeutics, Inc. (NASDAQ: ONTX), FSD Pharma Inc. (NASDAQ: HUGE) and Immatics N.V. (NASDAQ: IMTX) are among the biggest biopharma movers in Wednesday's session.
3 Biotech Stocks That Could Double In 12 Months
Biotech stocks are risky investment bets that can swing an investor's fortunes in a big way. An investment decision backed by careful scrutiny and analysis — of a company's pipeline, collaborations, fun...